Pixantrone's US filing completed for non-Hodgkin's lymphoma
This article was originally published in Scrip
Executive Summary
Cell Therapeutics has completed its NDA filing with the US FDA for its experimental chemotherapy drug pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).